Jingqi Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingqi Xie has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Keiko Shinjo
Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publications Tatsunori Nishimura
Division of Cancer Biology, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550
2 shared publications- Yutaka Kondo
Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publications - Akira Mamiya
Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Fumiharu Ohka
Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Hiroshi I. Suzuki
Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 179 (2) , 127-135
A stress granule-associated RNA-binding protein FAM120A drives cisplatin resistance in non-small cell lung cancer
Cisplatin-based chemotherapy is a standard treatment for non-small cell lung cancer (NSCLC), but drug resistance poses a major clinical challenge. Stress-adaptive mechanisms, such as stress granule (SG) formation, are increasingly recognized alternative pathways that facilitate cancer cell survival. Here, we identify the RNA-binding protein, family with sequence similarity 120A (FAM120A), as an SG-associated factor that drives cisplatin resistance in NSCLC. FAM120A expression was markedly elevated in cisplatin-resistant NSCLC cell lines and clinical tumor specimens and was essential for SG formation and cell survival following cisplatin-induced stress. We found that the intrinsically disordered RNA-binding domain of FAM120A is essential for its incorporation into SGs and for its cytoprotective function. Using enhanced cross-linking immunoprecipitation sequencing data and RNA immunoprecipitation-qPCR, we identified the long noncoding RNA, metastasis-associated lung adenocarcinoma transcript 1 as a key FAM120A interacting partner. MALAT1 levels were reduced upon FAM120A depletion, and overexpression of MALAT1 was sufficient to restore cisplatin resistance in these cells. These findings suggest that MALAT1 is an RNA species that is stabilized by FAM120A and involved in the cellular response to chemotherapy. Targeting this regulatory mechanism may offer new therapeutic strategies to overcome cisplatin resistance in NSCLC.
- 15 December 2025
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 179 (2) , 127-135
Open AccessA stress granule-associated RNA-binding protein FAM120A drives cisplatin resistance in non-small cell lung cancer
Cisplatin-based chemotherapy is a standard treatment for non-small cell lung cancer (NSCLC), but drug resistance poses a major clinical challenge. Stress-adaptive mechanisms, such as stress granule (SG) formation, are increasingly recognized alternative pathways that facilitate cancer cell survival. Here, we identify the RNA-binding protein, family with sequence similarity 120A (FAM120A), as an SG-associated factor that drives cisplatin resistance in NSCLC. FAM120A expression was markedly elevated in cisplatin-resistant NSCLC cell lines and clinical tumor specimens and was essential for SG formation and cell survival following cisplatin-induced stress. We found that the intrinsically disordered RNA-binding domain of FAM120A is essential for its incorporation into SGs and for its cytoprotective function. Using enhanced cross-linking immunoprecipitation sequencing data and RNA immunoprecipitation-qPCR, we identified the long noncoding RNA, metastasis-associated lung adenocarcinoma transcript 1 as a key FAM120A interacting partner. MALAT1 levels were reduced upon FAM120A depletion, and overexpression of MALAT1 was sufficient to restore cisplatin resistance in these cells. These findings suggest that MALAT1 is an RNA species that is stabilized by FAM120A and involved in the cellular response to chemotherapy. Targeting this regulatory mechanism may offer new therapeutic strategies to overcome cisplatin resistance in NSCLC.
- Open Access
- 22 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
TUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation
Oncogene-induced DNA replication stress (RS) and consequent pathogenic R-loop formation are known to impede S phase progression. Nonetheless, cancer cells continuously proliferate under such high-stressed conditions through incompletely understood mechanisms. Here, we report taurine upregulated gene 1 (TUG1) long noncoding RNA (lncRNA), which is highly expressed in many types of cancers, as an important regulator of intrinsic R-loop in cancer cells. Under RS conditions, TUG1 is rapidly upregulated via activation of the ATR-CHK1 signaling pathway, interacts with RPA and DHX9, and engages in resolving R-loops at certain loci, particularly at the CA repeat microsatellite loci. Depletion of TUG1 leads to overabundant R-loops and enhanced RS, leading to substantial inhibition of tumor growth. Our data reveal a role of TUG1 as molecule important for resolving R-loop accumulation in cancer cells and suggest targeting TUG1 as a potent therapeutic approach for cancer treatment.
- 22 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Open AccessTUG1-mediated R-loop resolution at microsatellite loci as a prerequisite for cancer cell proliferation
Oncogene-induced DNA replication stress (RS) and consequent pathogenic R-loop formation are known to impede S phase progression. Nonetheless, cancer cells continuously proliferate under such high-stressed conditions through incompletely understood mechanisms. Here, we report taurine upregulated gene 1 (TUG1) long noncoding RNA (lncRNA), which is highly expressed in many types of cancers, as an important regulator of intrinsic R-loop in cancer cells. Under RS conditions, TUG1 is rapidly upregulated via activation of the ATR-CHK1 signaling pathway, interacts with RPA and DHX9, and engages in resolving R-loops at certain loci, particularly at the CA repeat microsatellite loci. Depletion of TUG1 leads to overabundant R-loops and enhanced RS, leading to substantial inhibition of tumor growth. Our data reveal a role of TUG1 as molecule important for resolving R-loop accumulation in cancer cells and suggest targeting TUG1 as a potent therapeutic approach for cancer treatment.